Hepatoid adenocarcinoma of the lung with PD-L1 expression and the response to anti-PD-1 therapy: a case report

被引:1
|
作者
Li, Yan [1 ]
Liu, Lili [2 ]
Wang, Dongfeng [3 ]
Tan, Xiaojing [1 ]
Sui, Yanmin [1 ]
Yang, Honglan [1 ]
机构
[1] Dongying Peoples Hosp, Dept Oncol, Dongying, Shandong, Peoples R China
[2] Dongying Peoples Hosp, Dept Pathol, Dongying, Shandong, Peoples R China
[3] Dongying Peoples Hosp, Dept Chest Surg, Dongying, Shandong, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
hepatoid adenocarcinoma of the lung; alpha-fetoprotein; anti-PD-1; therapy; brain metastases; case report;
D O I
10.3389/fonc.2023.1257931
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatoid adenocarcinoma of the lung (HAL) is extremely rare; a standardized treatment strategy for HAL has not been established. The prognosis of patients with unresectable HAL is extremely poor. Here, we reported a 64-year-old male patient with unresectable alpha-fetoprotein-producing HAL who showed moderate harboring programmed death ligand 1 (PD-L1) expression and no targetable driver mutations. The patient was treated with brain radiotherapy, multiple lines of chemotherapies, and PD-1 inhibitor and achieved a survival rate of 9 months. The patient finally died because of the progression of brain metastasis. The case report provides valuable information for the treatment strategy development of advanced HAL patients and reminds us of the therapeutic particularity of brain metastasis.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
    Margarita Kirienko
    Martina Sollini
    Arturo Chiti
    Clinical and Translational Imaging, 2018, 6 : 417 - 427
  • [22] A random forest model to predict the efficacy of anti-PD-1/PD-L1 monoclonal antibody in lung adenocarcinoma
    Xie, Tongji
    Li, Yan
    Yang, Lin
    Wu, Lige
    Yuan, Hanqi
    Ying, Jianming
    Li Junling
    Xing, Puyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
    Sundararajan, Srinath
    Vogelzang, Nicholas J.
    FUTURE ONCOLOGY, 2015, 11 (16) : 2299 - 2306
  • [24] Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report
    Wu, Na
    Yang, Xiaoxin
    Zhai, Yan
    Lu, Wei
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (02) : 739 - 744
  • [25] Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies
    Liu, Shufang
    Niu, Wenquan
    JAMA ONCOLOGY, 2020, 6 (02) : 298 - 299
  • [26] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
    Chen, Gang
    Huang, Alexander C.
    Zhang, Wei
    Zhang, Gao
    Wu, Min
    Xu, Wei
    Yu, Zili
    Yang, Jiegang
    Wang, Beike
    Sun, Honghong
    Xia, Houfu
    Man, Qiwen
    Zhong, Wenqun
    Antelo, Leonardo F.
    Wu, Bin
    Xiong, Xuepeng
    Liu, Xiaoming
    Guan, Lei
    Li, Ting
    Liu, Shujing
    Yang, Ruifeng
    Lu, Youtao
    Dong, Liyun
    McGettigan, Suzanne
    Somasundaram, Rajasekharan
    Radhakrishnan, Ravi
    Mills, Gordon
    Lu, Yiling
    Kim, Junhyong
    Chen, Youhai H.
    Dong, Haidong
    Zhao, Yifang
    Karakousis, Giorgos C.
    Mitchell, Tara C.
    Schuchter, Lynn M.
    Herlyn, Meenhard
    Wherry, E. John
    Xu, Xiaowei
    Guo, Wei
    NATURE, 2018, 560 (7718) : 382 - +
  • [27] Prospect of combination of anti-PD-1/PD-L1 therapy and other therapeutics for treatment of lung cancer
    WANG Lu-yao
    YAO Rui-xue
    XU Qian-qian
    LIU Jia
    中国药理学与毒理学杂志, 2019, (10) : 888 - 888
  • [28] Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report
    Otani, Yoko
    Mori, Kiyoshi
    Morikawa, Nozomi
    Mizutani, Makiko
    Yasojima, Hiroyuki
    Masuyama, Misato
    Mano, Masayuki
    Masuda, Norikazu
    IMMUNOTHERAPY, 2021, 13 (03) : 189 - 194
  • [29] PD-L1 EXPRESSION IN SUBTYPES OF ADENOCARCINOMA OF THE LUNG
    Son, Choonhee
    CHEST, 2019, 156 (04) : 307A - 307A
  • [30] Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
    Sun, J.
    Yang, Q.
    Chen, M.
    Gu, J.
    Zheng, L.
    Yu, Y.
    Li, F.
    Zhang, L.
    Niu, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S451 - S451